Vicore Pharma Holding AB (publ) (STO:VICO)
Sweden · Delayed Price · Currency is SEK 10.72
+0.02 (0.19%)
Sep 2, 2026, 5:29 PM CET
Vicore Pharma Holding AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3.99 | 3.82 | 109.35 | - | - | - | |
Revenue Growth | -48.41% | -96.51% | - | - | - | - |
Gross Profit | 3.99 | 3.82 | 109.35 | - | - | - |
Selling, General & Admin | 94.24 | 67.91 | 50.44 | 44.6 | 37.53 | 21.61 |
Research & Development | 433.65 | 390.35 | 249.26 | 276.29 | 249.97 | 271.81 |
Operating Expenses | 527.89 | 458.26 | 299.71 | 320.89 | 287.49 | 293.42 |
Operating Income | -523.89 | -454.45 | -190.36 | -320.89 | -287.49 | -293.42 |
Interest Expense | - | -0.06 | -0.01 | -0 | -0.01 | -0.01 |
Interest & Investment Income | 70.76 | 23.89 | 21.08 | 10.54 | 0.91 | 0.65 |
Currency Exchange Gain (Loss) | -48.64 | -46.86 | 0.4 | -0.62 | -1.75 | -1.83 |
EBT Excluding Unusual Items | -501.78 | -477.47 | -168.89 | -310.97 | -288.34 | -294.61 |
Gain (Loss) on Sale of Investments | - | - | - | -0.36 | -0.47 | -2.12 |
Pretax Income | -501.78 | -477.47 | -168.89 | -311.33 | -288.81 | -296.74 |
Income Tax Expense | 0.26 | - | -0.26 | -0.38 | -0.38 | -0.25 |
Net Income | -502.04 | -477.47 | -168.63 | -310.94 | -288.42 | -296.48 |
Net Income to Common | -502.04 | -477.47 | -168.63 | -310.94 | -288.42 | -296.48 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 263 | 240 | 137 | 97 | 72 | 70 |
Shares Outstanding (Diluted) | 263 | 240 | 137 | 97 | 72 | 70 |
Shares Change | 32.83% | 75.30% | 41.72% | 33.71% | 3.64% | 28.44% |
EPS (Basic) | -1.91 | -1.99 | -1.23 | -3.22 | -3.99 | -4.25 |
EPS (Diluted) | -1.91 | -1.99 | -1.23 | -3.22 | -3.99 | -4.25 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -456.73 | -375.74 | -164.95 | -249.58 | -299.92 | -265.17 |
Free Cash Flow Per Share | -1.73 | -1.57 | -1.21 | -2.58 | -4.15 | -3.81 |
Gross Margin | 100.00% | 100.00% | 100.00% | - | - | - |
Operating Margin | -13116.97% | -11905.82% | -174.09% | - | - | - |
Profit Margin | -12569.76% | -12509.14% | -154.22% | - | - | - |
Free Cash Flow Margin | -11435.40% | -9843.78% | -150.85% | - | - | - |
EBITDA | - | -452.2 | -188.12 | -317.47 | -283.88 | -290.06 |
EBITDA Margin | - | - | -172.04% | - | - | - |
D&A For EBITDA | - | 2.24 | 2.24 | 3.42 | 3.61 | 3.36 |
EBIT | -523.89 | -454.45 | -190.36 | -320.89 | -287.49 | -293.42 |
EBIT Margin | - | - | -174.09% | - | - | - |